Neuren Pharmaceuticals Ltd., of Melbourne, Australia, received the initial payment of $10 million from Acadia Pharmaceuticals Inc., of San Diego, as part of their licensing agreement for Neuren's Rett syndrome and Fragile X syndrome treatment, trofinetide. (See BioWorld, Aug. 8, 2018.)